Sarah Hein, Ph.D., is the founding CEO of March Biosciences, a clinical-stage cell-therapy company targeting challenging hematological malignancies. Prior to cofounding March Biosciences, Dr. Hein was the founding Entrepreneur in Residence for the Texas Medical Center Innovation Accelerator for Cancer Therapeutics. Formerly, she was a cofounder and the vice president of Operations at Courier Therapeutics, a cancer immunotherapy startup acquired by Valo Health. She was also director of Research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her doctorate in Molecular Biology from Baylor College of Medicine.
